Innovent and Roche Enter into A Strategic Collaboration to Discover and Develop Multiple Products including Cellular Therapies and Bispecific Antibodies

信达生物与罗氏达成战略合作研发多个产品,包括细胞治疗和双特异性抗体

2020-06-09 08:30:27 CISION

本文共1427个字,阅读需4分钟

 Innovent Biologics, Inc. , a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced a strategic research and development collaboration with Roche covering multiple cell therapies and bispecific antibodies. The collaboration will focus on the discovery, clinical development and commercialization of bispecific antibodies and multiple cell therapies and will be directed to the treatment of hematological and solid cancers. Under the terms of the agreement, Innovent will pay upfront, development and commercial milestone payments, and royalties, to non-exclusively access certain Roche technologies that enable the discovery and development of specific 2:1 T-cell bispecific antibodies (TCB) and the universal CAR-T platform. Innovent will create, develop, manufacture, and commercialize the products. Roche retains an option right to license each product for ex-China development and commercialization. Should Roche exercise all of its options, it will pay option exercise payments totaling $140 million plus additional development, approval, and sales milestone payments up to $1.96 billion if all products are successfully developed and commercialized. Additionally, Roche will pay double-digit up to mid teen percentage royalties on each product. Dr. Michael Yu, Founder, Chairman and CEO of Innovent Biologics commented, "Innovent first entered the cellular therapy space a few years ago, and with this partnership with Roche we are taking a much bolder step forward as we build upon Roche's novel, universal CAR-T cell technology to enhance our cellular therapy discovery platform, and on Roche's 2:1 T-cell bispecific antibody platform for selected targets to discover, develop, and commercialize new proprietary bispecific molecules. We are excited about working together as we rapidly advance these technologies to proof of concept stage in China, with Roche retaining an ex-China licensing option to carry the Ex-China development forward thereafter, potentially benefiting patients globally."        About Innovent  Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop and commercialize high quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of cancer, metabolic, autoimmune and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK. Since its inception, Innovent has developed a fully-integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 17 in clinical development, 5 in Phase 3 or pivotal clinical trials, 4 under NDA reviews by the NMPA (3 under priority review status), while TYVYT® (sintilimab injection), officially approved for marketing in China in 2018, has been the only PD-1 inhibitor included in the NRDL since 2019. Innovent has built an international team of advanced talents in high-end biological drug development and commercialization, including many overseas experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi, and other international partners. Innovent strives to work with all relevant parties to help advance China's biopharmaceutical industry, improve drug availability to ordinary people and enhance the quality of the patients' lives. For more information, please visit: www.innoventbio.com. SOURCE Innovent Biologics, Inc. Related Links http://www.innoventbio.com
全球一流的生物制药公司 Innovation Biologics , Inc .研制、生产和商业化治疗癌症、代谢、自身免疫等重大疾病的优质药物,今天宣布与罗氏(Roche)公司开展战略研发合作,涵盖多种细胞治疗和双特异性抗体。 此次合作将集中于双特异性抗体和多种细胞疗法的发现、临床开发和商业化,并将致力于血液和实体癌的治疗。 根据协议条款, Innovation 将支付前期、开发和商业里程碑付款,以及使用费,以非专有访问某些罗氏(Roche)技术,使发现和开发特定2:1 T 细胞双特异性抗体( TCB )和通用 CAR-T 平台成为可能。创新将创造、开发、制造和商业化产品。罗氏(Roche)保留在中国以外开发和商业化的每个产品的许可权。如果罗氏(Roche)公司行使其所有的期权,它将支付总额为1.4亿美元的期权行权付款,加上额外的开发、批准和销售里程碑付款高达19.6亿美元,如果所有产品都成功开发和商业化。此外,罗氏(Roche)公司将支付两位数高达百分之十五的特许权使用费对每个产品。 Innovation Biologics 创始人、董事长兼首席执行官 Michael Yu 博士评论说:“ Innovant 几年前首先进入了细胞治疗领域,通过与罗氏(Roche)的合作,我们在罗氏的新型、通用 CAR-T 细胞技术的基础上迈出了更加大胆的一步,以增强我们的细胞治疗发现平台,以及罗氏(Roche)2:1 T 细胞双特异性抗体平台,用于选定的目标,以发现、开发和商业化新的专有双特异性分子。我们很高兴在快速推进这些技术以证明中国概念阶段的同时,与罗氏(Roche)合作,保留一个中国以外的许可选项,以推动中国前的发展,从而有可能使全球患者受益。”这是一个很好的例子 关于创新 本着“以诚信为先,以行动成功”的精神, Innovant 的使命是开发和商业化普通百姓都能负担得起的优质生物制药产品。Innovation 成立于2011年,致力于研发、制造和商业化用于治疗癌症、代谢、自身免疫等重大疾病的优质创新药物。2018年10月31日, Innovation 在香港联合交易所有限公司主板上市,股票代码:01801。香港。 Innovation 自成立以来,已开发出一个完整集成的多功能平台,包括研发、 CMC (化学、制造、控制)、临床开发和商业化能力。利用该平台,公司在肿瘤、代谢、自身免疫性疾病等主要治疗领域构建了23项宝贵资产的稳健管线,其中临床开发17项,3期或关键临床试验5项, NMPA 的 NDA 审评4项(处于优先审评状态3项),而 TYVYT ®(辛蒂利亚玛注射液)。2018年正式批准在中国上市,是2019年以来纳入 NRDL 的唯一 PD-1抑制剂。 英诺泰在高端生物药物研发和商业化方面建立了一支国际先进人才队伍,其中不乏海外专家。公司还与礼来(Eli Lilly)公司、 Adimab 公司、因塞特(Incyte)公司、 MD Anderson 癌症中心、 Hanmi 公司等国际合作伙伴开展战略合作。英诺珐公司努力与各方共同努力,帮助推进我国生物制药产业,提高老百姓的药品可获得性,提升患者生活质量。如需更多信息,请访问: www.invenovitbtio.com 。 SOURCE Innovate Biologics , Inc . 相关链接 http://www.innvenovitbtio.com

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文